Please login to the form below

Not currently logged in
Email:
Password:

Amgen posts decrease in earnings

Amgen's second quarter financial results hit by US healthcare reform fees

US pharmaceutical company Amgen has reported a 3 per cent decrease in net income for the second quarter of 2011 to $1.3bn.

The company reported a 4 per cent increase in sales during the three month period to $3.96bn.

Kevin Sharer, chairman and CEO, said: "Our products recorded a strong 8 per cent growth during the quarter. Our business has momentum and we expect to be at the upper end of our revenue and EPS [earnings per share] guidance."

Amgen said that its R&D expenses increased by 26 per cent in the quarter to $808m, reflecting the costs associated with late stage clinical programmes, it said. Meanwhile its selling, general and administrative expenses increased by 15 per cent in the second quarter to $1.1bn driven by the US Healthcare Reform Federal Exercise Fee of $47m.

1st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics